ClinicalTrials.gg
RecruitingNCT06857487QUIETUpdated Dec 1, 2025

Qingre Huatan Formula for the Prevention of Early Neurological Deterioration in Acute Ischemic Stroke

A Phase 1/2 interventional study of Qingre Huatan Formula and Qingre Huatan Formula placebo in Acute Ischemic Stroke, sponsored by Dongzhimen Hospital, Beijing. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-01.

Sponsored by Dongzhimen Hospital, Beijing · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Ischemic Stroke by Dongzhimen Hospital, Beijing — 6 open to participants now, 6 under way, none of them phase 3. Ischemic Stroke · Dongzhimen Hospital, Beijing.

Planned enrollment
8th of 10
72 · median 456
Started
2025
with 1 other
Phase 1/2
Only one
of the 16
Registered
15th of 16
by date

Among the 16 studies in Ischemic Stroke by Dongzhimen Hospital, Beijing, this one is the 8th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2025, is the only one in phase 1/2, and was the 15th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

6 of the 16 studies in Ischemic Stroke by Dongzhimen Hospital, Beijing are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Ischemic Stroke by Dongzhimen Hospital, Beijing, or all of them as a file.
02

Study summary

The purpose of this study is to assess the effectiveness and safety of Qingre Huatan formula versus placebo on preventing early neurological deterioration in patients with acute ischemic stroke within 48 hours after onset.

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Inpatients diagnosed with acute ischemic stroke. Inpatients diagnosed of acute ischemic stroke.
  2. Meet the criteria of TCM phlegm-heat syndrome
  3. Patients at high-risk of END : Magnetic resonance imaging (MRI) reveals new ischemic lesions, with DWI-ASPECTS score ≤ 7, or presence of at least two risk factors of END.
  4. Acute ischemic stroke within 48 hours after onset.
  5. Aged 18-80 years, male or female.
  6. The patient or representative has signed .

Exclusion criteria

Exclusion Criteria:

  1. Received or planned thrombolysis or endovascular therapy after onset.
  2. Suspected secondary stroke caused by brain tumor, brain trauma, hemopathy, etc.
  3. Already dependent in activities of daily living before the present acute stroke (defined as modified Rankin Scare score ≥2 )
  4. Diseases that cause motor dysfunction, including osteoarthritis, etc.
  5. Known severe liver or kidney dysfunction ( or aspartate transaminase > 2 times the value, serum creatinine > 1.5 times the upper limit of normal value)
  6. Known severe aphasia or mental illness affecting clinical information collection and evaluation.
  7. Pregnancy, potential pregnancy or breastfeeding.
  8. Currently participating in other clinical trials.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Qingre Huatan Formula

    Patients will receive orally administered Qingre Huatan Formula, combined with guidelines-based standard care.

    Drug: Qingre Huatan Formula · Other: Guidelines-based standard care

  • Placebo comparator
    Qingre Huatan Formula placebo

    Patients will receive orally administered Qingre Huatan Formula placebo, combined with guidelines-based standard care.

    Drug: Qingre Huatan Formula placebo · Other: Guidelines-based standard care

Interventions

  • DrugQingre Huatan Formula

    Qingre Huatan Formula, granules, 1 bag each time, twice a day, orally, continue for 10 days.

  • DrugQingre Huatan Formula placebo

    Qingre Huatan Formula placebo, granules, 1 bag each time, twice a day, orally, continue for 10 days.

  • OtherGuidelines-based standard care

    Guidelines-based standard care for acute ischemic stroke

06

What researchers measure

Primary outcomes

  1. The incidence of early neurological deterioration within 7 days of onset

    An increase of NIHSS ≥2 within 7 days of onset is considered as early neurological deterioration. The NIHSS (National Institute of Health Stroke Scale) is a neurological assessment tool for stroke patients, with scores ranging from 0 to 42.

    Time frame: Basline and Day 7

Secondary outcomes

  1. Change in National Institute of Health Stroke Scale scores from baseline to 10 days (after the treatment)

    The NIHSS (National Institute of Health Stroke Scale) is a neurological assessment tool for stroke patients, with scores ranging from 0 to 42. Scores of 0-1 indicate near normal status, 1-4 mild stroke, 5-15 moderate stroke, 16-20 moderate-to-severe stroke, and 21-42 severe stroke. It is primarily used to quickly assess stroke severity and guide treatment decisions.

    Time frame: Basline and 10 days after treatment initiation

  2. The proportion of patients with modified Rankin Scale score ≤2 on day 30

    The mRS (modified Rankin Scale) is an ordinal, graded interval scale that assigns patients among 7 global disability levels, which ranging from 0 (no symptom) to 5 (severe disability) and 6 (death).

    Time frame: Day 30

  3. The proportion of patients with modified Rankin Scale score ≤2 on day 90

    The mRS (modified Rankin Scale) is an ordinal, graded interval scale that assigns patients among 7 global disability levels, which ranging from 0 (no symptom) to 5 (severe disability) and 6 (death).

    Time frame: Day 90

  4. Activity of daily living of patients measured by Barthel Index score on day 30

    Barthel Index is a commonly used scale for measuring the activity of daily living of people. Score of 10-item scale ranges from 0 (worst) to 100 (best).

    Time frame: Day 30

  5. Activity of daily living of patients measured by Barthel Index score on day 90

    Barthel Index is a commonly used scale for measuring the activity of daily living of people. Score of 10-item scale ranges from 0 (worst) to 100 (best).

    Time frame: Day 90

  6. Incidence of treatment-related adverse events

    Number of patients with any adverse events during the study.

    Time frame: 90 days after treatment initiation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Zheng X, Yang Z, Wu H, Zhao M, Que C, Xiong X, Mu Y, Zhang G, Kang L, Gao Y, Lai X. Efficacy and safety of Qingre Huatan Formula for the prevention of early neurological deterioration in patients with acute ischemic stroke (QUIET): rationale and design for a randomized double-blind placebo-controlled study. Front Med (Lausanne). 2026 Apr 13;13:1754648. doi: 10.3389/fmed.2026.1754648. eCollection 2026. PubMed 42051694 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Oct 2026, 16 months after the start.

Of 27 phase 1/2 interventional studies under Ischemic Stroke, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 76. This study's planned 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2025
First posted
Mar 4, 2025
StartActual
Jun 13, 2025
Primary completionEst.
Oct 24, 2026
CompletionEst.
Oct 29, 2026
Last update
Dec 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06857487
Lead sponsor
Dongzhimen Hospital, Beijing
Responsible party
Ying Gao (Professor, Dongzhimen Hospital, Beijing) — Principal investigator
First posted
Mar 4, 2025
Start date
Jun 13, 2025
Primary completion
Oct 24, 2026 (estimated)
Completion
Oct 29, 2026 (estimated)
Last update
Dec 1, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion